Rodica BÄ**J**aÈā^M

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11081428/publications.pdf

Version: 2024-02-01

		1163117	839539
19	946	8	18
papers	citations	h-index	g-index
19	19	19	1414
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neuroprotection in Stroke—Focus on the Renin-Angiotensin System: A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 3876.	4.1	5
2	Stroke secondary to giantâ€'cell arteritis: A literature review. Experimental and Therapeutic Medicine, 2021, 22, 876.	1.8	12
3	Reviewing the Significance of Blood–Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment. International Journal of Molecular Sciences, 2021, 22, 8370.	4.1	54
4	The Role of Biomarkers in Atherothrombotic Strokeâ€"A Systematic Review. International Journal of Molecular Sciences, 2021, 22, 9032.	4.1	11
5	Postpartum Acute Basilar Artery Occlusion Secondary to Vertebral Artery Dissection. Case Report and Literature Review. The Journal of Critical Care Medicine, 2021, 7, 294-301.	0.7	O
6	Prevalence and Clinical Characteristics of Subclavian Steal Phenomenon/Syndrome in Patients with Acute Ischemic Stroke. Journal of Clinical Medicine, 2021, 10, 5237.	2.4	2
7	Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients – An In Vitro Study. Frontiers in Immunology, 2021, 12, 743010.	4.8	2
8	Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab. Brain Sciences, 2020, 10, 802.	2.3	2
9	The action of TH17 cells on blood brain barrier in multiple sclerosis and experimental autoimmune encephalomyelitis. Human Immunology, 2020, 81, 237-243.	2.4	58
10	The direct deleterious effect of Th17 cells in the nervous system compartment in multiple sclerosis and experimental autoimmune encephalomyelitis: one possible link between neuroinflammation and neurodegeneration. Romanian Journal of Laboratory Medicine, 2020, 28, 9-17.	0.2	6
11	Plasma Biomarkers as Potential Predictors of Functional Dependence in Daily Life Activities after Ischemic Stroke: A Single Center Study. Annals of Indian Academy of Neurology, 2020, 23, 496-503.	0.5	4
12	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	13.7	684
13	Severe Fatal Systemic Embolism Due to Non-Bacterial Thrombotic Endocarditis as the Initial Manifestation of Gastric Adenocarcinoma: Case Report. The Journal of Critical Care Medicine, 2018, 4, 68-73.	0.7	3
14	Predicting functional outcome of ischemic stroke patients in Romania based on plasma CRP, sTNFR-1, D-Dimers, NGAL and NSE measured using a biochip array. Acta Pharmacologica Sinica, 2018, 39, 1228-1236.	6.1	33
15	The Matrix Metalloproteinases Panel in Multiple Sclerosis Patients Treated with Natalizumab: A Possible Answer to Natalizumab Non- Responders. CNS and Neurological Disorders - Drug Targets, 2018, 17, 464-472.	1.4	10
16	Stroke Secondary to Traumatic Carotid Artery Injury – A Case Report. The Journal of Critical Care Medicine, 2018, 4, 23-28.	0.7	5
17	Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response. CNS and Neurological Disorders - Drug Targets, 2017, 16, 93-101.	1.4	12
18	Malignant Middle Cerebral Artery Infarction Secondary to Traumatic Bilateral Internal Carotid Artery Dissection. A Case Report. The Journal of Critical Care Medicine, 2016, 2, 135-141.	0.7	9

Rodica BÄ∫laÈ™a

#	Article	lF	CITATIONS
19	Serum levels of IL-17A in patients with relapsing–remitting multiple sclerosis treated with interferon-β. Multiple Sclerosis Journal, 2013, 19, 885-890.	3.0	34